Pharsight

Mylan Speciality Lp patents expiration

1. Astepro patents expiration

ASTEPRO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Nov, 2025

(2 years from now)

US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine
Nov, 2025

(2 years from now)

US8071073 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Jun, 2028

(4 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

2. Dymista patents expiration

DYMISTA's oppositions filed in EPO
DYMISTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(3 months ago)

US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(3 months ago)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(30 days ago)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Dec, 2023

(2 months from now)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(5 months from now)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(2 years from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2026

(2 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis; Treatment of allergic rhinitis, including seasonal allergic rhinitis; Allergic rhinitis; Treatment of symptoms of seasonal allergic rhinitis; Relief of symptom...

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage

DYMISTA family patents

Family Patents

3. Edluar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Apr, 2027

(3 years from now)

US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(7 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage

EDLUAR family patents

Family Patents

4. Elestrin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7198801 MYLAN SPECIALITY LP Formulations for transdermal or transmucosal application
Jun, 2022

(1 year, 3 months ago)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 15 December, 2006

Treatment: NA

Dosage: GEL, METERED;TRANSDERMAL

More Information on Dosage

ELESTRIN family patents

Family Patents

5. Epi E Z Pen Jr patents expiration

EPI E Z PEN JR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 11 months from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 11 months from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(1 year, 11 months from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 11 months from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 11 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 22 December, 1987

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

How can I launch a generic of EPI E Z PEN JR before it's drug patent expiration?
More Information on Dosage

EPI E Z PEN JR family patents

Family Patents

6. Rowasa patents expiration

ROWASA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7645801 MYLAN SPECIALITY LP Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Jul, 2027

(3 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 24 December, 1987

Treatment: NA

Dosage: ENEMA;RECTAL

More Information on Dosage

ROWASA family patents

Family Patents

7. Tobi Podhaler patents expiration

TOBI PODHALER's oppositions filed in EPO
TOBI PODHALER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421166 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(9 months ago)

US7368102 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycosides
Dec, 2022

(9 months ago)

US8715623 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(9 months ago)

US7516741 MYLAN SPECIALITY LP Aerosolization apparatus with feedback mechanism
Jan, 2024

(3 months from now)

USRE47526 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Apr, 2024

(6 months from now)

US8069851 MYLAN SPECIALITY LP Aeorosolization apparatus with air inlet shield
Sep, 2024

(11 months from now)

US11484671 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2024

(1 year, 1 month from now)

US8664187 MYLAN SPECIALITY LP Methods of treatment of endobronchial infections
Jun, 2025

(1 year, 8 months from now)

US7559325 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Oct, 2025

(2 years from now)

US8869794 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncturing member
Sep, 2028

(4 years from now)

US10207066 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2030

(7 years from now)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 March, 2013

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER;INHALATION

More Information on Dosage

TOBI PODHALER family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic